Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coeptis Therapeutics Holdings (COEPW) Equity Average (2021 - 2025)

Coeptis Therapeutics Holdings has reported Equity Average over the past 5 years, most recently at $12.2 million for Q4 2025.

  • Quarterly results put Equity Average at $12.2 million for Q4 2025, up 192.11% from a year ago — trailing twelve months through Dec 2025 was $12.2 million (up 192.11% YoY), and the annual figure for FY2025 was $8.7 million, up 315.87%.
  • Equity Average for Q4 2025 was $12.2 million at Coeptis Therapeutics Holdings, up from $8.7 million in the prior quarter.
  • Over the last five years, Equity Average for COEPW hit a ceiling of $12.2 million in Q4 2025 and a floor of -$8.8 million in Q2 2021.
  • Median Equity Average over the past 5 years was $2.3 million (2024), compared with a mean of $2.3 million.
  • Biggest five-year swings in Equity Average: crashed 151.68% in 2024 and later surged 3419.85% in 2025.
  • Coeptis Therapeutics Holdings' Equity Average stood at -$1.6 million in 2021, then surged by 449.35% to $5.6 million in 2022, then plummeted by 75.82% to $1.4 million in 2023, then soared by 209.02% to $4.2 million in 2024, then skyrocketed by 192.11% to $12.2 million in 2025.
  • The last three reported values for Equity Average were $12.2 million (Q4 2025), $8.7 million (Q3 2025), and $7.3 million (Q2 2025) per Business Quant data.